- Home
- KNSA vs BCAT Comparison
KNSA vs BCAT Comparison
Compare KNSA & BCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSA
- BCAT
- Stock Information
- Founded
- KNSA 2015
- BCAT 2020
- Country
- KNSA United Kingdom
- BCAT United States
- Employees
- KNSA N/A
- BCAT N/A
- Industry
- KNSA Biotechnology: Pharmaceutical Preparations
- BCAT Finance/Investors Services
- Sector
- KNSA Health Care
- BCAT Finance
- Exchange
- KNSA Nasdaq
- BCAT Nasdaq
- Market Cap
- KNSA 1.9B
- BCAT 1.5B
- IPO Year
- KNSA 2018
- BCAT N/A
- Fundamental
- Price
- KNSA $28.44
- BCAT $14.75
- Analyst Decision
- KNSA Strong Buy
- BCAT
- Analyst Count
- KNSA 5
- BCAT 0
- Target Price
- KNSA $38.80
- BCAT N/A
- AVG Volume (30 Days)
- KNSA 707.0K
- BCAT 308.8K
- Earning Date
- KNSA 07-22-2025
- BCAT 01-01-0001
- Dividend Yield
- KNSA N/A
- BCAT 9.38%
- EPS Growth
- KNSA N/A
- BCAT N/A
- EPS
- KNSA N/A
- BCAT 1.43
- Revenue
- KNSA $481,166,000.00
- BCAT N/A
- Revenue This Year
- KNSA $37.21
- BCAT N/A
- Revenue Next Year
- KNSA $5.32
- BCAT N/A
- P/E Ratio
- KNSA N/A
- BCAT $11.41
- Revenue Growth
- KNSA 59.45
- BCAT N/A
- 52 Week Low
- KNSA $17.38
- BCAT $13.67
- 52 Week High
- KNSA $30.69
- BCAT $16.38
- Technical
- Relative Strength Index (RSI)
- KNSA 55.24
- BCAT 45.35
- Support Level
- KNSA $27.62
- BCAT $14.72
- Resistance Level
- KNSA $28.69
- BCAT $14.91
- Average True Range (ATR)
- KNSA 1.13
- BCAT 0.15
- MACD
- KNSA -0.28
- BCAT -0.06
- Stochastic Oscillator
- KNSA 45.78
- BCAT 5.26
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.